1. Pink Sheet

Cancer 'Moonshot' Recommendations On R&D Have Strong Patient Focus

 
• By Kate Rawson

Blue ribbon panel has plenty of industry-friendly recommendations on ways to accelerate oncology science, but with the clock ticking down on the Obama Administration, the question is whether the recommendations have any political traction.

Colorful-pills-black-background-moon_1200x675

Recommendations from Vice President Joe Biden’s Cancer “Moonshot” Blue Ribbon Panel have a specific emphasis on patient-focused research, new areas for oncology R&D and the establishment of a national clinical trial data network for “one-stop, free access” to patient data from studies across the country.

The Blue Ribbon Panel was established to identify key scientific opportunities to meet the Moonshot’s ambitious directive: to make a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By Vibha Sharma

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 
• By Eliza Slawther

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.